Covid-19 roundup: Mod­er­na has filed for vac­cine use in chil­dren; Claim­ing lead­er­ship to com­bat Covid-19, US pledges to do­nate 500M dos­es of Pfiz­er/BioN­Tech vac­cines through CO­V­AX

Just days af­ter Mod­er­na’s vac­cine was sub­mit­ted for ap­proval for use in chil­dren in the EU and Cana­da, the com­pa­ny has an­nounced it has filed for emer­gency use au­tho­riza­tion with the FDA for the ad­min­is­tra­tion in teens be­tween 12 and 18.

Mod­er­na an­nounced in May that its Phase II/III study of the vac­cine in ado­les­cents met the pri­ma­ry end­points in near­ly 2,500 pa­tients, show­ing an ef­fi­ca­cy of 100% against se­vere symp­to­matic Covid-19. Be­cause chil­dren are less like­ly to de­vel­op se­ri­ous side ef­fects, the tri­al al­so looked at milder cas­es than ex­am­ined in the adult study. The study found that the vac­cine was 93% ef­fec­tive at stop­ping mild cas­es 14 days af­ter pa­tients were dosed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER